EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials.
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...
Hosted on MSN
In first, circumventing law, judge okays ALS patient’s right to die; he donates his organs
Michael Podolsky, a 44-year-old man diagnosed with amyotrophic lateral sclerosis (ALS), died on September 25 at Sheba Medical Center in Tel HaShomer after a Tel Aviv District Court granted his request ...
WASHINGTON (AP) — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by ...
An Upper Gwynedd woman is turning her personal battle with ALS into a mission to improve emergency response care, writes ...
SAVANNAH, GEORGIA — Remote monitoring of respiratory scores in patients with amyotrophic lateral sclerosis (ALS) helps predict the best timing for the introduction of bilevel positive airway pressure ...
10don MSN
Months later, ALS patient gets disabled parking spot she sought for freedom to simply leave home
More than four months after a Chicago woman battling ALS was told she couldn't get a disabled parking placard in front of her ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A simple non-invasive hair-based test could one day help with early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results